Literature DB >> 1326994

HIV-1 and HIV-2 infections in men attending sexually transmitted disease clinics in Abidjan, Côte d'Ivoire.

M O Diallo1, A N Ackah, M F Lafontaine, R Doorly, R Roux, J M Kanga, P Heroin, K M De Cock.   

Abstract

OBJECTIVE: (1) To determine the prevalence of HIV-1 and HIV-2 infections and associated risk factors in men attending Abidjan's three sexually transmitted disease (STD) clinics; (2) to examine the use of such sites for epidemiological surveillance.
DESIGN: Cross-sectional study.
SETTING: Abidjan's two main STD clinics (Clinics A and T), and the University Hospital Dermatology outpatients clinic. PATIENTS: Consecutive patients with genitourinary symptoms. MAIN OUTCOME MEASURES: Prevalence of reactivity to HIV-1, HIV-2, and both viruses; descriptive characteristics of clinic attenders; clinical diagnoses of STD; risk factors associated with HIV-1 and HIV-2 positivity.
RESULTS: The overall prevalence of HIV (HIV-1 and/or HIV-2) infection was 21% (250 out of 1169; 16% HIV-1, 2% HIV-2, 3% dual reactivity). Overall prevalence varied by clinic: University Hospital Dermatology outpatients clinic, 39%; Clinic T, 19%; Clinic A, 10%. Men with STD had an overall prevalence of 31% (155 out of 506), compared with 14% in men without physical signs of STD (odds ratio 2.6, 95% confidence interval 2.0-3.6). The highest prevalence, 46%, was in men with genital ulcer disease. Risk factors associated with HIV-1 as well as with HIV-2 infection after multivariate analysis were a history of sex with prostitutes, lack of circumcision, being unskilled, and a history of prior genital ulcer. Current genital ulcer, current STD and positive Treponema pallidum haemagluttination assay were associated with HIV-1 and dual reactivity.
CONCLUSIONS: Risk factors for HIV-2 infection in men attending Abidjan STD clinics were broadly similar to those for HIV-1 infection. HIV-1 infection was more strongly associated with current STD. Important differences between the three clinics were observed in STD prevalence and type, and HIV seroprevalence. Such differences should be taken into account in the planning of HIV serosurveillance in STD clinics.

Entities:  

Mesh:

Year:  1992        PMID: 1326994     DOI: 10.1097/00002030-199206000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

Review 1.  Immunological functions of the human prepuce.

Authors:  P M Fleiss; F M Hodges; R S Van Howe
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

Review 2.  Soap and water prophylaxis for limiting genital ulcer disease and HIV-1 infection in men in sub-Saharan Africa.

Authors:  N O'Farrell
Journal:  Genitourin Med       Date:  1993-08

3.  Therapeutic algorithms for the management of sexually transmitted diseases at the peripheral level in Côte d'Ivoire: assessment of efficacy and cost.

Authors:  G La Ruche; F Lorougnon; N Digbeu
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  Excluding blood donors at high risk of HIV infection in a west African city.

Authors:  R Schutz; D Savarit; J C Kadjo; V Batter; N Kone; G La Ruche; A Bondurand; K M De Cock
Journal:  BMJ       Date:  1993-12-11

5.  The potential impact of male circumcision on HIV in Sub-Saharan Africa.

Authors:  Brian G Williams; James O Lloyd-Smith; Eleanor Gouws; Catherine Hankins; Wayne M Getz; John Hargrove; Isabelle de Zoysa; Christopher Dye; Bertran Auvert
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

6.  Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies.

Authors:  Li Chen; Prabhat Jha; Bridget Stirling; Sema K Sgaier; Tina Daid; Rupert Kaul; Nico Nagelkerke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

7.  Male Circumcision and the Epidemic Emergence of HIV-2 in West Africa.

Authors:  João Dinis Sousa; Marina Padrão Temudo; Barry Stephen Hewlett; Ricardo Jorge Camacho; Viktor Müller; Anne-Mieke Vandamme
Journal:  PLoS One       Date:  2016-12-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.